Expanded Access Program for Olaparib Tablets as Maintenance Therapy in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

Part of paid clinical trials in Duarte, California.

Sponsor
AstraZeneca
Study ID
NCT03079687
Status
Approved For Marketing

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - 120 Years
Healthy Volunteers
Not accepted

Interventions

  • Olaparib tablets — DRUG
    Patients will receive olaparib tablets 300mg (two 150mg tablets) twice daily.

Study Details

This is an open-label, single-arm, international, multicenter Multiple Patient Expanded Access Program (MPEAP). The program is designed to provide treatment access to olaparib tablets for patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer without other treatment options or eligible for an olaparib clinical trials.

Key Dates

Status verified
Oct 2017

Locations (13)

FacilityCityStateZIPSite coordinators
Research SiteDuarteCalifornia91010-
Research SiteNewport BeachCalifornia92663-
Research SiteRosevilleCalifornia95661-
Research SiteGainesvilleFlorida32608-
Research SiteScarboroughMaine04074-
Research SiteBaltimoreMaryland21201-
Research SiteRochesterMinnesota55905-
Research SiteColumbiaMissouri65212-
Research SiteAlbuquerqueNew Mexico87106-
Research SiteDurhamNorth Carolina27710-
Research SiteWinston-SalemNorth Carolina27157-1023-
Research SiteClevelandOhio44195-
Research SitePortlandOregon97239-

Find similar trials in Duarte, CA

By condition
Ovarian cancer
By specialty
OncologyGynecologic oncologyWomen's health
By research site
Research Site· Duarte, CAResearch Site· Newport Beach, CAResearch Site· Roseville, CAResearch Site· Gainesville, FLResearch Site· Scarborough, MEResearch Site· Baltimore, MD

Related Studies